A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Phase 1/2 Terminated
31 enrolled 19 charts
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Phase 1/2 Completed
15 enrolled 10 charts
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Phase 1/2 Completed
58 enrolled 24 charts
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
Phase 1/2 Completed
154 enrolled 22 charts
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
Phase 1/2 Completed
78 enrolled 11 charts
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Phase 1/2 Terminated
3 enrolled 10 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Phase 1/2 Completed
21 enrolled 22 charts
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
Phase 1/2 Completed
97 enrolled 40 charts
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Phase 1/2 Terminated
24 enrolled 12 charts
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Phase 1/2 Terminated
24 enrolled 18 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1/2 Completed
184 enrolled 36 charts
5-AZ
Phase 1/2 Terminated
11 enrolled 10 charts
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Phase 1/2 Terminated
10 enrolled 8 charts
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Phase 1/2 Terminated
9 enrolled 13 charts